ClinicalTrials.gg
Active, not recruitingNCT04280081LIBRETTO-321Updated Aug 7, 2026Results posted

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

A Phase 2 interventional study of Selpercatinib in Solid Tumor and Medullary Thyroid Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.

Enrollment
11th of 16
77 · median 151
Started
2020
with 1 other
Phase 2
3 of 18
none open now
Primary completion
2021-03
later than 0 of 10 live
Registered
6th of 18
by date
Lead sponsor
1 of 18
Eli Lilly and Company

Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 6th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Medullary with a site in China, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

03

Conditions studied

  • Solid Tumor
  • Medullary Thyroid Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • NSCLC
  • Targeted Therapy
  • Medullary Thyroid Carcinoma
  • Thyroid Cancer
  • RET Alteration
  • MTC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a locally advanced or solid tumor.
  • Evidence of a RET gene alteration in tumor and/or blood.
  • Measurable or non- as determined by (RECIST) v1.1.
  • (ECOG) performance status score of 0, 1, or 2, with no sudden deterioration 2 weeks prior to the first dose of study treatment.
  • Archived tumor tissue sample available for cohort 1 and 2.
  • Cohorts 1 and 2: failed or intolerant to standard of care.
  • Cohorts 1-2: enrollment will be restricted to participants with evidence of a RET gene alteration in tumor (i.e., not just blood). However, a positive germline DNA test for a RET gene mutation as defined in the protocol is acceptable in the absence of tumor tissue testing for participants with MTC.
  • Cohorts 1-2: at least one measurable lesion as defined by RECIST v1.1 and not previously irradiated (unless progressive disease for the irradiated lesion[s] has been radiographically documented).

Exclusion criteria

Exclusion Criteria:

  • Cohorts 1-2, an additional validated oncogenic driver that could cause resistance to selpercatinib treatment if known.
  • Prior treatment with a selective RET inhibitor(s) (including selective RET inhibitor(s), such as BLU-667, RXDX-105, etc).
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 except where otherwise noted in this eligibility criteria at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum therapy-related neuropathy.
  • Symptomatic primary central nervous system (CNS) tumor, symptomatic , , or untreated spinal cord compression.
  • active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of selpercatinib or prolongation of the corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds.
  • History of (known HIV 1/2 antibodies positive); participants with unknown HIV status do not need to be tested.
  • History of active (known positive hepatitis B surface antigen [HbsAg] and quantitative hepatitis B DNA greater than the upper limit of detection of the assay) or C (known positive antibody and quantitative hepatitis C RNA greater than the upper limit of detection of the assay); participants with unknown hepatitis B/hepatitis C status do not need to be tested.
  • Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
  • Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
  • Uncontrolled symptomatic hyperthyroidism or hypothyroidism
  • Uncontrolled symptomatic hypercalcemia or hypocalcemia.
  • Concurrent use of drugs known to prolong QTc.
  • Pregnancy or lactation. Breast-feeding should be interrupted when selpercatinib is started; breast-feeding can be resumed 3 months after discontinuation of selpercatinib.
  • Active second other than minor treatment of indolent cancers with prior sponsor approval.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Selpercatinib

    Selpercatinib 160 milligrams (mg) administered orally twice daily (BID).

    Drug: Selpercatinib

Interventions

  • Administered orally

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)

    ORR is the summary measure of best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. BOR is defined as the best response designation for each participant that is recorded between the date of the first dose of selpercatinib and the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first, and subsequently confirmed. BOR will be categorized as complete response (CR), partial response (PR). CR is defined as Disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR At least 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD.

    Time frame: Date of First Dose to Disease Progression or Death (up to 12 Months)

  2. Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC

    ORR is the summary measure of best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. BOR is defined as the best response designation for each participant that is recorded between the date of the first dose of selpercatinib and the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first, and subsequently confirmed. BOR will be categorized as complete response (CR), partial response (PR). CR is defined as Disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR At least 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD.

    Time frame: Date of First Dose to Disease Progression or Death (Up to 12 months)

Secondary outcomes

  1. Enrolled Population: Duration of Response (DoR) as Assessed by IRC

    DOR is defined as the number of months from the start date of PR or CR (whichever response is recorded first), and subsequently confirmed, to the date of disease progression or death, whichever occurs earlier.

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 11 Months)

  2. Enrolled Population: Time to Response (TTR) as Assessed by IRC

    TTR is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of objective response (CR or PR, whichever occurs earlier) that is subsequently confirmed.

    Time frame: Date of First Dose to First Occurrence of Confirmed Tumor Response (Up to 6 months)

  3. Enrolled Population: Time to Best Response (TTBR) as Assessed by IRC

    TTR is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of objective response (CR or PR, whichever occurs earlier) that is subsequently confirmed.

    Time frame: Date of First Dose to First Occurrence of PR (If Subject's Best Overall Response [BOR] is PR) or CR (If Subject's BOR is CR) (Up to 8 months)

  4. Enrolled Population: Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR, or Stable Disease (SD) With a Duration of At Least 16 or More Weeks as Assessed by IRC

    CBR based on the percentage of participants with best overall response of CR, PR, or stable disease (SD) lasting 16 or more weeks following initiation of selpercatinib as assessed by IRC. CR is defined as disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions) and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

    Time frame: Baseline through Disease Progression or Death Due to Any Cause (Up to 12 Months)

  5. Enrolled Population: Progression Free Survival (PFS) as Assessed by IRC

    PFS is defined as the number of months elapsed between the date of the first dose and the earliest date of documented disease progression or death (whatever the cause). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest sum on study) for target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5.0 mm. Progressive disease for non-target lesion is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Baseline to Progressive Disease or Death from Any Cause (Up to 12 Months)

  6. Enrolled Population: Overall Survival (OS)

    OS is defined as the number of months elapsed between the date of the first dose and the date of death (whatever the cause). Participants who are alive or lost to follow-up as of the data cutoff date will be right-censored.

    Time frame: Baseline to Date of Death from Any Cause (Up to 12 Months)

  7. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Selpercatinib

    Serial blood samples for intensive PK monitoring will be collected for 12 participants.

    Time frame: PK: Cycle 1 Day 1: Predose, 1 h, 2, h, 4 h, 8 h, 12 h postdose PK: Cycle 1 Day 8: Predose, 1 h, 2, h, 4 h, 8 h postdose

07

Results

Posted Jun 2, 2022

Participant flow

Enrollment for this study was based on tumor type.

Participant flow — Overall Study
MilestoneSelpercatinib
Started77
Enrolled: all nsclc47
Enrolled: all tc1
Enrolled: all mtc29
Pas: ret fusion positive nsclc26
Pas: ret fusion positive tc1
Pas: advance ret-mutant mtc26
Completed65
Not completed12
Withdrew: Adverse event4
Withdrew: Death2
Withdrew: Progressive disease6

Outcome measures

PrimaryPrimary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)

ORR is the summary measure of best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. BOR is defined as the best response designation for each participant that is recorded between the date of the first dose of selpercatinib and the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first, and subsequently confirmed. BOR will be categorized as complete response (CR), partial response (PR). CR is defined as Disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR At least 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD.

Time frame:
Date of First Dose to Disease Progression or Death (up to 12 Months)
Reported as:
Number · percentage of participants
Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)
percentage of participantsRET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1RET Fusion Positive Thyroid Cancer (TC) Cohort 1RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2
Complete Response3.8 (0.1 to 19.6)0 (0.0 to 97.5)7.7 (0.9 to 25.1)
Partial Response65.4 (44.3 to 82.8)100.0 (2.5 to 100.0)50.0 (29.9 to 70.1)
Overall Response (CR/PR)69.2 (48.2 to 85.7)100.0 (2.5 to 100.0)57.7 (36.9 to 76.6)
PrimaryEnrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC

ORR is the summary measure of best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. BOR is defined as the best response designation for each participant that is recorded between the date of the first dose of selpercatinib and the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first, and subsequently confirmed. BOR will be categorized as complete response (CR), partial response (PR). CR is defined as Disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR At least 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD.

Time frame:
Date of First Dose to Disease Progression or Death (Up to 12 months)
Reported as:
Number · percentage of participants
Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC
percentage of participantsNon-small Cell Lung Cancer (All NSCLC)Thyroid Cancer (All TC)Medullary Thyroid Cancer (All MTC)
Complete Response6.4 (1.3 to 17.5)0 (0.0 to 97.5)10.3 (2.2 to 27.4)
Partial Response59.6 (44.3 to 73.6)100.0 (2.5 to 100.0)48.3 (29.4 to 67.5)
Overall Response (CR/PR)66.0 (50.7 to 79.1)100.0 (2.5 to 100.0)58.6 (38.9 to 76.5)
SecondaryEnrolled Population: Duration of Response (DoR) as Assessed by IRC

DOR is defined as the number of months from the start date of PR or CR (whichever response is recorded first), and subsequently confirmed, to the date of disease progression or death, whichever occurs earlier.

Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 11 Months)
Reported as:
Median · months
Enrolled Population: Duration of Response (DoR) as Assessed by IRC
monthsAll NSCLCAll TCAll MTC
Enrolled Population: Duration of Response (DoR) as Assessed by IRCNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryEnrolled Population: Time to Response (TTR) as Assessed by IRC

TTR is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of objective response (CR or PR, whichever occurs earlier) that is subsequently confirmed.

Time frame:
Date of First Dose to First Occurrence of Confirmed Tumor Response (Up to 6 months)
Reported as:
Median · months
Enrolled Population: Time to Response (TTR) as Assessed by IRC
monthsAll NSCLCAll TCAll MTC
Enrolled Population: Time to Response (TTR) as Assessed by IRC1.84 (1.74 to 1.87)1.74 (1.74 to 1.74)1.84 (1.81 to 3.71)
SecondaryEnrolled Population: Time to Best Response (TTBR) as Assessed by IRC

TTR is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of objective response (CR or PR, whichever occurs earlier) that is subsequently confirmed.

Time frame:
Date of First Dose to First Occurrence of PR (If Subject's Best Overall Response [BOR] is PR) or CR (If Subject's BOR is CR) (Up to 8 months)
Reported as:
Geometric mean · months
Enrolled Population: Time to Best Response (TTBR) as Assessed by IRC
monthsAll NSCLCAll TCAll MTC
Enrolled Population: Time to Best Response (TTBR) as Assessed by IRC1.84 (1.77 to 1.87)1.74 (1.74 to 1.74)1.87 (1.81 to 5.16)
SecondaryEnrolled Population: Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR, or Stable Disease (SD) With a Duration of At Least 16 or More Weeks as Assessed by IRC

CBR based on the percentage of participants with best overall response of CR, PR, or stable disease (SD) lasting 16 or more weeks following initiation of selpercatinib as assessed by IRC. CR is defined as disappearance of all target lesions. Any pathologic nodes (whether target or non-target lesions) must have a reduction in short axis diameter (SAD) to less than 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters (SOD) (LD for non-nodal lesions) and SAD for nodal lesions) of target lesions, taking as reference the baseline sum LD. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

Time frame:
Baseline through Disease Progression or Death Due to Any Cause (Up to 12 Months)
Reported as:
Number · percentage of participants
Enrolled Population: Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR, or Stable Disease (SD) With a Duration of At Least 16 or More Weeks as Assessed by IRC
percentage of participantsAll NSCLCAll TCAll MTC
Enrolled Population: Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR, or Stable Disease (SD) With a Duration of At Least 16 or More Weeks as Assessed by IRC76.6 (62.0 to 87.7)100.0 (2.5 to 100.0)65.5 (45.7 to 82.1)
SecondaryEnrolled Population: Progression Free Survival (PFS) as Assessed by IRC

PFS is defined as the number of months elapsed between the date of the first dose and the earliest date of documented disease progression or death (whatever the cause). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest sum on study) for target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5.0 mm. Progressive disease for non-target lesion is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Baseline to Progressive Disease or Death from Any Cause (Up to 12 Months)
Reported as:
Median · months
Enrolled Population: Progression Free Survival (PFS) as Assessed by IRC
monthsAll NSCLCAll TCAll MTC
Enrolled Population: Progression Free Survival (PFS) as Assessed by IRCNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryEnrolled Population: Overall Survival (OS)

OS is defined as the number of months elapsed between the date of the first dose and the date of death (whatever the cause). Participants who are alive or lost to follow-up as of the data cutoff date will be right-censored.

Time frame:
Baseline to Date of Death from Any Cause (Up to 12 Months)
Reported as:
Median · months
Enrolled Population: Overall Survival (OS)
monthsAll NSCLCAll TCAll MTC
Enrolled Population: Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Selpercatinib

Serial blood samples for intensive PK monitoring will be collected for 12 participants.

Time frame:
PK: Cycle 1 Day 1: Predose, 1 h, 2, h, 4 h, 8 h, 12 h postdose PK: Cycle 1 Day 8: Predose, 1 h, 2, h, 4 h, 8 h postdose
Reported as:
Geometric mean · nanogram * hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Selpercatinib
nanogram * hour per milliliter (ng*h/mL)Selpercatinib
Cycle 1 Day 111700 ± 56.8
Cycle 1 Day 837900 ± 54

Adverse events

Collected over Baseline up to 12 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selpercatinib3/77 (3.9%)17/77 (22.1%)75/77 (97.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSelpercatinib
Hepatic function abnormalHepatobiliary disorders3/77
HypersensitivityImmune system disorders3/77
Aspartate aminotransferase increasedInvestigations3/77
Platelet count decreasedInvestigations3/77
PyrexiaGeneral disorders2/77
Alanine aminotransferase increasedInvestigations2/77
Benign prostatic hyperplasiaReproductive system and breast disorders1/44
Prostatic obstructionReproductive system and breast disorders1/44
Cushing's syndromeEndocrine disorders1/77
PancreatitisGastrointestinal disorders1/77
Most frequent other events
Showing 10 of 65
Most frequent other events
EventSelpercatinib
Alanine aminotransferase increasedInvestigations50/77
Aspartate aminotransferase increasedInvestigations47/77
Blood bilirubin increasedInvestigations30/77
Platelet count decreasedInvestigations29/77
HypertensionVascular disorders27/77
HypoalbuminaemiaMetabolism and nutrition disorders26/77
DiarrhoeaGastrointestinal disorders25/77
White blood cell count decreasedInvestigations25/77
Dry mouthGastrointestinal disorders22/77
Blood alkaline phosphatase increasedInvestigations21/77

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Selpercatinib
Mean50.60 ± 12.87
Sex: Female, Male
Sex: Female, Male(Participants)Selpercatinib
Female33
Male44
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selpercatinib
American Indian or Alaska Native0
Asian77
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Selpercatinib
China77
08

Study locations

13 sites
09

References and documents

Publications

  • Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, Zhou J, Guo Y, Shao J, Zhang W. Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial. Ther Adv Med Oncol. 2025 Jan 1;17:17588359241307199. doi: 10.1177/17588359241307199. eCollection 2025. PubMed 39759832 ↗
  • Lu S, Zheng X, Sun Y, Huang D, Wu L, Ji Q, Zhou C, Zhou J, Guo Y, Ge M, Ding D, Shao J, Zhang W, Gao M, Cheng Y. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial. Ther Adv Med Oncol. 2023 Aug 25;15:17588359231189429. doi: 10.1177/17588359231189429. eCollection 2023. PubMed 37655205 ↗
  • Cheng Y, Huang D, Zhou J, Zhou C, Sun Y, Wu L, Guo Y, Jingxin S, Zhang W, Lu S. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial. JCO Precis Oncol. 2023 Jun;7:e2200708. doi: 10.1200/PO.22.00708. PubMed 37315261 ↗
  • Zheng X, Ji Q, Sun Y, Ge M, Zhang B, Cheng Y, Lei S, Shi F, Guo Y, Li L, Chen L, Shao J, Zhang W, Gao M. Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study. Ther Adv Med Oncol. 2022 Aug 29;14:17588359221119318. doi: 10.1177/17588359221119318. eCollection 2022. PubMed 36062046 ↗
  • Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, Guo Y, Shao J, Zhang W, Zhou J. Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321). Ther Adv Med Oncol. 2022 Jul 28;14:17588359221105020. doi: 10.1177/17588359221105020. eCollection 2022. PubMed 35923928 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Mar 2021, 12 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Feb 21, 2020
StartActual
Mar 16, 2020
Primary completionActual
Mar 25, 2021
CompletionEst.
Nov 2028
Results first posted
Jun 2, 2022
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04280081
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Mar 16, 2020
Primary completion
Mar 25, 2021
Completion
Nov 2028 (estimated)
Results posted
Jun 2, 2022
Last update
Aug 7, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion